Here are five facts:
1. The award grants funds of up to $1.2 million.
2. The funds will be used for pre-clinical research focusing on the application of the company’s biosynthetic scaffold, InQu, to repair chondral defects.
3. The two-year study is being led by Anthony J. Ward, PhD, principal scientist at ISTO Technologies.
4. The study aims to pave the way for clinical studies to support commercial approval of InQu for cartilage repair.
5. ISTO is a privately held orthobiologics company focusing on spinal therapies and sports medicine.
More articles on devices:
Smith & Nephew Q2 revenue up 5%: 8 things to know
5 key notes on NuVasive’s 10% share growth yesterday — What it means going forward
SeaSpine Q2 revenue down 6% in first report as independent company: 6 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
